117 related articles for article (PubMed ID: 2419945)
1. Fibrinolytic activity of prostacyclin and iloprost in patients with peripheral arterial disease.
Musiał J; Wilczyńska M; Sładek K; Cierniewski CS; Nizankowski R; Szczeklik A
Prostaglandins; 1986 Jan; 31(1):61-70. PubMed ID: 2419945
[TBL] [Abstract][Full Text] [Related]
2. The inhibitory effect of aspirin on fibrinolysis is reversed by iloprost, a prostacyclin analogue.
Bertelé V; Mussoni L; Pintucci G; del Rosso G; Romano G; de Gaetano G; Libretti A
Thromb Haemost; 1989 Apr; 61(2):286-8. PubMed ID: 2473539
[TBL] [Abstract][Full Text] [Related]
3. Defective fibrinolytic response in atherosclerotic patients--effect of iloprost and its possible mechanism of action.
Bertelé V; Mussoni L; del Rosso G; Pintucci G; Carriero MR; Merati MG; Libretti A; de Gaetano G
Thromb Haemost; 1988 Oct; 60(2):141-4. PubMed ID: 2464198
[TBL] [Abstract][Full Text] [Related]
4. Prostacyclin and molsidomine synergise in their fibrinolytic and anti-platelet actions in patients with peripheral arterial disease.
Bieroń K; Grodzińska L; Kostka-Trabka E; Gryglewski RJ
Wien Klin Wochenschr; 1993; 105(1):7-11. PubMed ID: 8438599
[TBL] [Abstract][Full Text] [Related]
5. Sodium nitroprusside modulates the fibrinolytic system in the rabbit.
Lidbury PS; Korbut R; Vane JR
Br J Pharmacol; 1990 Nov; 101(3):527-30. PubMed ID: 2127549
[TBL] [Abstract][Full Text] [Related]
6. Fibrinolytic activity in retinal vein occlusion.
Abu El-Asrar AM; Abdel Gader AG; Al-Amro S; Al-Momem AK
Int Ophthalmol; 1997-1998; 21(6):343-8. PubMed ID: 9869344
[TBL] [Abstract][Full Text] [Related]
7. Prostacyclin is required for t-PA release after venous occlusion.
Iacoviello L; De Curtis A; D'Adamo MC; Amore C; Buczko W; De Gaetano G; Donati MB
Am J Physiol; 1994 Feb; 266(2 Pt 2):H429-34. PubMed ID: 7511345
[TBL] [Abstract][Full Text] [Related]
8. Effect of prostacyclin (PGI2) on platelets and fibrinolytic activity in patients with arteriosclerosis obliterans.
Dembińska-Kieć A; Kostka-Trabka E; Zumda A; Byrska-Danek A; Bierón K; Grodzińska L; Kedzior A; Zelazny T
Pharmacol Res Commun; 1982 Jun; 14(6):485-98. PubMed ID: 6750655
[No Abstract] [Full Text] [Related]
9. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
Siegbahn A; Ruusuvaara L
Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
[TBL] [Abstract][Full Text] [Related]
10. Stimulation of the plasma fibrinolytic activity in rats by the prostacyclin analogue CG 4203.
Schneider J
Thromb Res; 1987 Oct; 48(2):233-44. PubMed ID: 3321546
[TBL] [Abstract][Full Text] [Related]
11. In vitro analysis of synergistic effects of fibrinolytic agents and prostacyclin analogues.
Spiecker M; Heinke B; Meyer J; Darius H
Haemostasis; 1997; 27(4):184-92. PubMed ID: 9483173
[TBL] [Abstract][Full Text] [Related]
12. Effects of iloprost, a prostacyclin analog derivative, on renal plasma flow, renal function, and renin-aldosterone system in humans.
Angeli P; Gatta A; Caregaro L; Menon F; Sacerdoti D; Merkel C; Visoná A; Lusiani L; Pagnan A
Clin Pharmacol Ther; 1988 Aug; 44(2):211-6. PubMed ID: 2456174
[TBL] [Abstract][Full Text] [Related]
13. [Plasminogen activators (t-PA and u-PA) and other fibrinolysis parameters in patients with atherosclerosis obliterans and diabetic macroangiopathy].
Zalewska-Rydzkowska D; Rość D; Ponikowska I; Michalski A; Graczykowska-Koczorowska A; Rydzkowski M
Pol Merkur Lekarski; 2001 Nov; 11(65):414-7. PubMed ID: 11852811
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of fibrinolytic capacity by a combined assay system for tissue-type plasminogen activator antigen and function using monoclonal anti-tissue-type plasminogen activator antibodies.
Wojta J; Turcu L; Wagner OF; Korninger C; Binder BR
J Lab Clin Med; 1987 Jun; 109(6):665-71. PubMed ID: 3108431
[TBL] [Abstract][Full Text] [Related]
15. Myocardial ischemia induced by prostacyclin and iloprost.
Bugiardini R; Galvani M; Ferrini D; Gridelli C; Tollemeto D; Mari L; Puddu P; Lenzi S
Clin Pharmacol Ther; 1985 Jul; 38(1):101-8. PubMed ID: 2408809
[TBL] [Abstract][Full Text] [Related]
16. Euglobulin clot lysis time reveals a high frequency of fibrinolytic activation in trauma.
Ilich A; Kumar V; Ferrara MJ; Henderson MW; Noubouossie DF; Jenkins DH; Kozar RA; Park MS; Key NS
Thromb Res; 2021 Aug; 204():22-28. PubMed ID: 34111811
[TBL] [Abstract][Full Text] [Related]
17. Tolerance and pharmacology of ciprostene, a stable epoprostenol (prostacyclin) analogue in humans.
Linet OI; Nishizawa EE; Schaub RG; VanderLugt JT; Greenwald CA
J Clin Pharmacol; 1986 Feb; 26(2):131-40. PubMed ID: 3005377
[TBL] [Abstract][Full Text] [Related]
18. Fibrinolysis during normal human pregnancy: complex inter-relationships between plasma levels of tissue plasminogen activator and inhibitors and the euglobulin clot lysis time.
Wright JG; Cooper P; Astedt B; Lecander I; Wilde JT; Preston FE; Greaves M
Br J Haematol; 1988 Jun; 69(2):253-8. PubMed ID: 3134043
[TBL] [Abstract][Full Text] [Related]
19. PAI-1 plays an important role in the expression of t-PA activity in the euglobulin clot lysis by controlling the concentration of free t-PA.
Urano T; Sumiyoshi K; Pietraszek MH; Takada Y; Takada A
Thromb Haemost; 1991 Oct; 66(4):474-8. PubMed ID: 1796399
[TBL] [Abstract][Full Text] [Related]
20. Effect of prostacyclin on fibrinolytic activity in patients with arteriosclerosis obliterans.
Dembinska-Kiec A; Kostka-Trabka E; Gryglewski RJ
Thromb Haemost; 1982 Apr; 47(2):190. PubMed ID: 7048622
[No Abstract] [Full Text] [Related]
[Next] [New Search]
